D
Defence Therapeutics Inc
CNSX:DTC
Defence Therapeutics Inc
CNSX:DTC
Price:
0.52
CAD
-1.89%
Market Closed
Market Cap:
CA$29.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
D
|
Defence Therapeutics Inc
CNSX:DTC
|
CA |
|
Elevra Lithium Ltd
ASX:ELV
|
AU |
|
M
|
Meren Energy Inc
F:AFZ0
|
CA |
|
A
|
Avanti Gold Corp
CNSX:AGC
|
CA |
Cash Flow Statement
Cash Flow Statement
Defence Therapeutics Inc
Defence Therapeutics Inc
Currency: CAD
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||
| Net Income |
(2)
|
(3)
|
(4)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(7)
|
(0)
|
(7)
|
(7)
|
(13)
|
(12)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
6
|
6
|
6
|
6
|
0
|
1
|
1
|
1
|
1
|
|
| Other Non-Cash Items |
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
0
|
6
|
6
|
6
|
6
|
1
|
1
|
1
|
1
|
1
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
0
|
(0)
|
(0)
|
(0)
|
0
|
1
|
1
|
1
|
(0)
|
0
|
2
|
3
|
3
|
2
|
1
|
(0)
|
(1)
|
(2)
|
(2)
|
|
| Cash from Operating Activities |
(1)
N/A
|
(2)
-104%
|
(4)
-66%
|
(5)
-33%
|
(6)
-20%
|
(6)
+0%
|
(6)
0%
|
(7)
-7%
|
(7)
-4%
|
0
N/A
|
1
+715%
|
2
+98%
|
(4)
N/A
|
(3)
+35%
|
(2)
+26%
|
(3)
-51%
|
(3)
-9%
|
(4)
-24%
|
(5)
-17%
|
|
| Investing Cash Flow | ||||||||||||||||||||
| Capital Expenditures |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Investing Activities |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(0)
N/A
|
(0)
+89%
|
0
N/A
|
(0)
N/A
|
(0)
-27%
|
(0)
+3%
|
(0)
+9%
|
0
N/A
|
0
-90%
|
(0)
N/A
|
(0)
-72%
|
|
| Financing Cash Flow | ||||||||||||||||||||
| Net Issuance of Common Stock |
9
|
6
|
7
|
1
|
1
|
1
|
2
|
2
|
6
|
(1)
|
(1)
|
(4)
|
2
|
0
|
2
|
5
|
5
|
0
|
4
|
|
| Net Issuance of Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
(0)
|
(2)
|
(2)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
2
|
2
|
|
| Other |
(1)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Cash from Financing Activities |
8
N/A
|
6
-25%
|
6
+10%
|
1
-87%
|
1
+25%
|
1
+8%
|
2
+54%
|
4
+130%
|
8
+109%
|
(1)
N/A
|
(3)
-160%
|
(6)
-106%
|
2
N/A
|
2
+0%
|
2
+14%
|
5
+131%
|
5
-1%
|
6
+40%
|
6
-10%
|
|
| Change in Cash | ||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Change in Cash |
7
N/A
|
4
-46%
|
3
-26%
|
(4)
N/A
|
(5)
-19%
|
(5)
+2%
|
(4)
+11%
|
(3)
+39%
|
1
N/A
|
(1)
N/A
|
(2)
-97%
|
(5)
-122%
|
(3)
+41%
|
(1)
+55%
|
(0)
+82%
|
2
N/A
|
1
-25%
|
2
+86%
|
1
-63%
|
|
| Free Cash Flow | ||||||||||||||||||||
| Free Cash Flow |
(1)
N/A
|
(2)
-104%
|
(4)
-66%
|
(5)
-33%
|
(6)
-20%
|
(6)
+0%
|
(6)
0%
|
(7)
-8%
|
(7)
-4%
|
0
N/A
|
1
+820%
|
2
+70%
|
(4)
N/A
|
(3)
+34%
|
(2)
+31%
|
(3)
-51%
|
(3)
-9%
|
(4)
-24%
|
(5)
-17%
|
|
Switch to:
Switch to:
See Also
Discover More
